Roxadustat

• Background :

  Roxadustat (808118-40-3) is a pan-prolyl hydroxylase domain (PHD) inhibitor (IC50 for PHD2 = 591 nM) 1 that stabilizes hypoxia-inducible factor (HIF) leading to erythropoiesis. Currently in clinical trials for treatment of anemia related to chronic kidney disease.2 Roxadustat accelerated cutaneous wound healing and shortened healing time via improvement in epidermal stem cell proliferation and motility3 and increasing angiogenesis4. It displayed radioprotective effects in haematopoietic systems via up-regulation of HIF-1.5 Roxadustat displayed protective effects against atherosclerosis via activation of adipose HIF-2.6

• Conjugation :

  Unconjugated

• Buffer :

  Off-white or white solid

• Storage Conditions :

  -20°C